News in other languages: SUSMED,Inc.

23-08-25	DTx von SUSMED wurde in Japan für die Behandlung von Schlaflosigkeit zugelassen
22-07-14	Aculys Pharma und SUSMED schließen Vertrag über Durchführung von weltweit erster klinischer Studie mit Blockchain-Technologie

More news

Managers and Directors: SUSMED,Inc.

Manager	Title	Age	Since
Taro Ueno PSD	President	45	2016-01-31
Tomomitsu Motohashi CTO	Chief Tech/Sci/R&D Officer	43	2019-08-31
Takayuki Obara ADM	Chief Administrative Officer	49	2021-04-30

Director	Title	Age	Since
Kenta Nagao BRD	Director/Board Member	67	2024-08-31
Makiko Yamamoto BRD	Director/Board Member	55	2024-08-31
Kuniaki Kaga BRD	Director/Board Member	75	2020-12-31

More insiders

Other IT Services & Consulting

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUSMED,INC.	-9.21%	-18.58%	-70.32%	-79.93%	32.36M
IBM	-0.85%	-5.14%	-20.14%	+65.65%	234B
SALESFORCE, INC.	-3.94%	-7.47%	-15.45%	+2.98%	183B
ACCENTURE PLC	-1.76%	+5.37%	+5.12%	-16.90%	157B
SNOWFLAKE INC.	+2.35%	-16.47%	+4.19%	+83.93%	95B
CLOUDFLARE, INC.	+9.91%	-13.39%	+17.61%	+317.18%	87.07B
TATA CONSULTANCY SERVICES LTD.	+0.11%	+0.83%	-16.44%	-25.44%	95.55B
RELX PLC	-2.20%	+3.46%	-11.74%	+6.38%	72.27B
INFOSYS LIMITED	+1.20%	+3.04%	-19.52%	-14.95%	50.04B
HCL TECHNOLOGIES LIMITED	+0.66%	+2.57%	-5.83%	+13.72%	40.97B
Average	-0.04%	-3.82%	-13.25%	+35.26%	101.42B
Weighted average by Cap.	+0.64%	-2.80%	-8.32%	+46.01%

See all sector performances

Susmed Inc is a Japan-based company mainly engaged in the digital therapeutics (DTx) development business. The Company operates through two business segments. The DTx Product segment is engaged in the development of application software products for treating diseases such as insomnia, breast cancer, chronic kidney diseases and others. The DTx Platform segment is engaged in the provision of general-purpose clinical trial systems and machine learning automatic analysis systems, as well as the provision of DTx development support services using systems.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
26-11-06	JP¥276.00	-9.21%	246,000
26-11-05	JP¥304.00	-2.56%	245,200
26-11-04	JP¥312.00	-3.11%	215,000
26-11-02	JP¥322.00	-3.01%	121,200
26-10-30	JP¥332.00	-2.06%	101,300

Delayed Quote Japan Exchange

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SUSMED,Inc.

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Japan Exchange 01:30:00 2026-11-06 EST			5-day change	1st Jan Change
276.00 ^JPY	-9.21%		-18.58%	-67.30%

25-03-23	SUSMED,Inc. announced that it has received funding from East Ventures Pte. Ltd.	CI
24-09-22	SUSMED,Inc.(TSE:4263) dropped from S&P Global BMI Index	CI

Market Cap	4.64B 29.28M 26.27M 24M 21.93M 41.35M 2.75B 42.65M 287M 116M 1.47B 110M 108M	P/E 2025	-34.4x	P/E 2026	-38.2x
Enterprise Value	942M 5.95M 5.34M 4.87M 4.45M 8.4M 558M 8.66M 58.37M 23.51M 298M 22.33M 21.85M	EV / Sales 2025	12.7x	EV / Sales 2026	21.9x
Free-Float	48.16%	Yield 2025 *	-	Yield 2026	-

25-03-23	SUSMED,Inc. announced that it has received funding from East Ventures Pte. Ltd.	CI
24-09-22	SUSMED,Inc.(TSE:4263) dropped from S&P Global BMI Index	CI
23-09-17	SUSMED,Inc.(TSE:4263) added to S&P Global BMI Index	CI
22-10-04	Walgreens Boots Alliance, Inc. Joins Sustainable Medicines Partnership	CI
22-07-12	Aculys Pharma and SUSMED Enter into A Contract to Conduct the Clinical Trial Utilizing Blockchain Technology	CI
22-06-20	Certain Common Stock of SUSMED,Inc. are subject to a Lock-Up Agreement Ending on 21-JUN-2022.	CI
22-03-22	Certain Common Stock of SUSMED,Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2022.	CI
22-03-09	CollaboCreate Co., Ltd. announced that it has received funding from SUSMED,Inc.	CI
21-12-28	Shionogi Signs up to $41 Million Commercialization Contract for Insomnia App	MT
21-12-27	Shionogi & Co., Ltd. Announces Commercialization Agreement with SUSMED Co., Ltd. for Digital Therapeutic App for Insomnia	CI
21-12-24	SUSMED,Inc. has completed an IPO in the amount of ¥3.65613 billion.	CI
21-11-19	SUSMED,Inc. has filed an IPO.	CI
20-10-29	SUSMED Co., Ltd. announced that it has received funding from Suzuken Co., Ltd.	CI

11-04	World-First Achievement: SUSMED's Blockchain-Based Clinical Trial System Supports Successful Marketing Authorization for Pharmaceutical Product	BU
23-08-25	SUSMED’s DTx Approved in Japan for the Treatment of Insomnia	BU
22-07-12	Aculys Pharma and SUSMED Have Entered into a Contract to Conduct the World's First Clinical Trial Utilizing Blockchain Technology	BU

SUSMED,Inc. Stock

Stocks

4263

JP3319150003

IT Services & Consulting

Valuation: SUSMED,Inc.

Chart: SUSMED,Inc.

Latest news: SUSMED,Inc.

Press Releases: SUSMED,Inc.

News in other languages: SUSMED,Inc.

Quotes and Performance

Price Extremes

Managers and Directors: SUSMED,Inc.

Other IT Services & Consulting

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 day	-9.21%
1 week	-18.58%
Current month	-16.87%
1 month	-32.85%
3 months	-61.13%
6 months	-70.10%
Current year	-67.30%

	2025	2026
Net sales	462M 2.92M 2.62M 2.39M 2.18M 4.12M 274M 4.25M 28.62M 11.53M 146M 10.95M 10.71M	497M 3.14M 2.81M 2.57M 2.35M 4.43M 294M 4.57M 30.78M 12.4M 157M 11.77M 11.52M
Net income	-298M -1.88M -1.69M -1.54M -1.41M -2.66M -177M -2.74M -18.46M -7.44M -94.3M -7.06M -6.91M	-382M -2.41M -2.16M -1.98M -1.81M -3.4M -226M -3.51M -23.66M -9.53M -121M -9.05M -8.86M
Net Debt	-4.4B -27.75M -24.9M -22.75M -20.79M -39.19M -2.61B -40.43M -272M -110M -1.39B -104M -102M	-3.7B -23.33M -20.94M -19.13M -17.48M -32.96M -2.19B -33.99M -229M -92.27M -1.17B -87.61M -85.73M

1 week	274	328
1 month	274	409
Current year	274	1,231
1 year	274	1,231
3 years	274	1,512
5 years	274	2,500
10 years	274	2,500